Influenza surveillance capacity improvements in Africa during 2011-2017.


Journal

Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007

Informations de publication

Date de publication:
07 2021
Historique:
received: 03 09 2020
accepted: 06 09 2020
pubmed: 6 11 2020
medline: 26 11 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

Influenza surveillance helps time prevention and control interventions especially where complex seasonal patterns exist. We assessed influenza surveillance sustainability in Africa where influenza activity varies and external funds for surveillance have decreased. We surveyed African Network for Influenza Surveillance and Epidemiology (ANISE) countries about 2011-2017 surveillance system characteristics. Data were summarized with descriptive statistics and analyzed with univariate and multivariable analyses to quantify sustained or expanded influenza surveillance capacity in Africa. Eighteen (75%) of 24 ANISE members participated in the survey; their cumulative population of 710 751 471 represent 56% of Africa's total population. All 18 countries scored a mean 95% on WHO laboratory quality assurance panels. The number of samples collected from severe acute respiratory infection case-patients remained consistent between 2011 and 2017 (13 823 vs 13 674 respectively) but decreased by 12% for influenza-like illness case-patients (16 210 vs 14 477). Nine (50%) gained capacity to lineage-type influenza B. The number of countries reporting each week to WHO FluNet increased from 15 (83%) in 2011 to 17 (94%) in 2017. Despite declines in external surveillance funding, ANISE countries gained additional laboratory testing capacity and continued influenza testing and reporting to WHO. These gains represent important achievements toward sustainable surveillance and epidemic/pandemic preparedness.

Sections du résumé

BACKGROUND
Influenza surveillance helps time prevention and control interventions especially where complex seasonal patterns exist. We assessed influenza surveillance sustainability in Africa where influenza activity varies and external funds for surveillance have decreased.
METHODS
We surveyed African Network for Influenza Surveillance and Epidemiology (ANISE) countries about 2011-2017 surveillance system characteristics. Data were summarized with descriptive statistics and analyzed with univariate and multivariable analyses to quantify sustained or expanded influenza surveillance capacity in Africa.
RESULTS
Eighteen (75%) of 24 ANISE members participated in the survey; their cumulative population of 710 751 471 represent 56% of Africa's total population. All 18 countries scored a mean 95% on WHO laboratory quality assurance panels. The number of samples collected from severe acute respiratory infection case-patients remained consistent between 2011 and 2017 (13 823 vs 13 674 respectively) but decreased by 12% for influenza-like illness case-patients (16 210 vs 14 477). Nine (50%) gained capacity to lineage-type influenza B. The number of countries reporting each week to WHO FluNet increased from 15 (83%) in 2011 to 17 (94%) in 2017.
CONCLUSIONS
Despite declines in external surveillance funding, ANISE countries gained additional laboratory testing capacity and continued influenza testing and reporting to WHO. These gains represent important achievements toward sustainable surveillance and epidemic/pandemic preparedness.

Identifiants

pubmed: 33150650
doi: 10.1111/irv.12818
pmc: PMC8189239
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

495-505

Informations de copyright

© 2020 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.

Références

Influenza Other Respir Viruses. 2018 Jan;12(1):30-37
pubmed: 29243402
Influenza Other Respir Viruses. 2021 Jul;15(4):495-505
pubmed: 33150650
PLoS One. 2014 Aug 18;9(8):e105543
pubmed: 25133576
PLoS One. 2016 Apr 27;11(4):e0153003
pubmed: 27119988
Pediatr Infect Dis J. 2015 Jan;34(1):66-72
pubmed: 25093972
BMC Public Health. 2014 Jan 16;14:41
pubmed: 24433304
PLoS One. 2015 Jun 11;10(6):e0128580
pubmed: 26068416
Bull World Health Organ. 2018 Feb 1;96(2):122-128
pubmed: 29403115
PLoS One. 2019 Jul 15;14(7):e0219012
pubmed: 31306466
Vaccine. 2019 May 21;37(23):3002-3005
pubmed: 31027926
BMC Infect Dis. 2016 Dec 13;16(1):757
pubmed: 27964716
Influenza Other Respir Viruses. 2018 Jan;12(1):38-45
pubmed: 29197152
Influenza Other Respir Viruses. 2018 May;12(3):360-373
pubmed: 29210203
Influenza Other Respir Viruses. 2018 Nov;12(6):695-705
pubmed: 30120818
Influenza Other Respir Viruses. 2013 Nov;7(6):1328-35
pubmed: 23551904
BMC Health Serv Res. 2014 May 09;14:209
pubmed: 24886275
J Trop Pediatr. 2012 Apr;58(2):102-6
pubmed: 21653546
Public Health. 2011 May;125(5):247-56
pubmed: 21524774
Vaccine. 2016 Feb 17;34(8):1086-90
pubmed: 26782740
Vaccine. 2019 Aug 14;37(35):5089-5095
pubmed: 31288998
Influenza Other Respir Viruses. 2018 Jan;12(1):46-53
pubmed: 29243406
J Clin Microbiol. 2013 Dec;51(12):4055-9
pubmed: 24088846
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):540-544
pubmed: 32379727
Influenza Other Respir Viruses. 2019 Sep;13(5):484-495
pubmed: 31187609
Emerg Infect Dis. 2011 Apr;17(4):619-25
pubmed: 21470450
Influenza Other Respir Viruses. 2019 Mar;13(2):138-147
pubmed: 30596225
J Infect Dis. 2008 Aug 1;198(3):305-11
pubmed: 18558871
PLoS Med. 2016 Mar 24;13(3):e1001977
pubmed: 27011229
J Infect Dis. 2012 Dec 15;206 Suppl 1:S14-21
pubmed: 23169960
Ghana Med J. 2012 Dec;46(4):219-24
pubmed: 23661840

Auteurs

Ledor S Igboh (LS)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
London School of Hygiene and Tropical Medicine, London, UK.

Meredith McMorrow (M)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.

Stefano Tempia (S)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
MassGenics, Atlanta, GA, USA.
National Influenza Center, Johannesburg, South Africa.

Gideon O Emukule (GO)

Centers for Disease Control and Prevention, Nairobi, Kenya.

Ndahwouh Talla Nzussouo (N)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
MassGenics, Atlanta, GA, USA.
Centers for Disease Control and Prevention, Accra, Ghana.

Margaret McCarron (M)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Thelma Williams (T)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Vashonia Weatherspoon (V)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Ann Moen (A)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Derrar Fawzi (D)

Institut Pasteur of Algeria, Algiers, Algeria.

Richard Njouom (R)

Center Pasteur du Cameroon, Yaounde, Cameroon.

Emmanuel Nakoune (E)

Institut Pasteur d'Bangui, Bangui, Central African Republic.

Coulibaly Dauoda (C)

National Institute Public Hygiene/Ministry of Health, Abidjan, Cote d'Ivoire.

Hugo Kavunga-Membo (H)

Institut National de Recherche Bio-medicale, Kinshasa, Democratic Republic of Congo.

Mary Okeyo (M)

National Public Health Institute, Nairobi, Kenya.

Jean-Michel Heraud (JM)

Virology Unit, National Influenza Centre, Institute Pasteur de Madagascar, Antananarivo, Madagascar.

Ivan Kiggundu Mambule (IK)

Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

Samba Ousmane Sow (SO)

Central National Influenza Laboratory/Ministry of Health, Bamako, Mali.

Almiro Tivane (A)

Instituto Nacional de Saude, Moputo, Mozambique.

Adamou Lagare (A)

Center de Recherche Medicale et Sanitaire, Niamey, Niger.

Adedeji Adebayo (A)

Nigeria Centers for Disease Control, Abuja, Nigeria.

Ndongo Dia (N)

Institut Pasteur de Dakar, Dakar, Senegal.

Vida Mmbaga (V)

National Reference Laboratory, Dar es Salaam, Tanzania.

Issaka Maman (I)

National Influenza Reference Laboratory, Lome, Togo.

Julius Lutwama (J)

Uganda Virus Research Institute, Entebbe, Uganda.

Paul Simusika (P)

National Influenza Center, University of Zambia Teaching Hospital, Lusaka, Zambia.

Sibongile Walaza (S)

School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
National Influenza Center, Johannesburg, South Africa.
Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.

Punam Mangtani (P)

London School of Hygiene and Tropical Medicine, London, UK.

Patrick Nguipdop-Djomo (P)

London School of Hygiene and Tropical Medicine, London, UK.

Cheryl Cohen (C)

School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
National Influenza Center, Johannesburg, South Africa.
Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.

Eduardo Azziz-Baumgartner (E)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH